2012 Research Annual Report

Cancer and Blood Diseases Institute

Division Details

Division Data Summary

Research and Training Details

Number of Faculty41
Number of Joint Appointment Faculty10
Number of Research Fellows9
Number of Research Students1
Number of Support Personnel217
Peer Reviewed Publications144

Clinical Activities and Training

Number of Clinical Staff19
Number of Clinical Fellows17
Number of Other Students7
Inpatient Encounters23,569
Outpatient Encounters15,475

Division Photo

Group photo of the CBDI
Left to Right: J Palumbo, J Perentesis, Y Zheng, S Davies


Significant Accomplishments

Significant Accomplishments

Gene therapy for SCID

Children with severe combined immune deficiency (SCID) are born lacking an essential gene that allows the immune system to fight infections. Untreated, SCID is fatal, with the children typically dying of overwhelming infection in the first two years of life. Children with SCID can be successfully treated with a bone marrow transplant that replaces the defective immune system cells with new ones. Unfortunately, some children with SCID will not have a suitable donor, and some who do have a transplant will have serious complications. A multi-center international gene therapy study, using a viral vector manufactured at Cincinnati Children’s, takes the child’s own cells and inserts a normal copy of the defective gene into the child’s own cells. With this approach there is no need for a matched donor and no need for chemotherapy, which leads to fewer complications. Lisa Filipovich, MD, is leading the study at Cincinnati Children’s and the first child has been enrolled and treated. We anticipate that gene therapy will become an important treatment option for babies with SCID, and may allow cure for all the children with fewer complications.

Participation in Clinical Trial Consortia Grows

With the acceptance of our application to join the National Cancer Institute-funded Pediatric Brain Tumor Consortium (PBTC), Cincinnati Children’s became the only pediatric cancer program in the US participating in all four selective national early-phase clinical research consortia: the NCI Pediatric Phase I/Pilot Consortium, the NCI New Approaches to Neuroblastoma Consortium, the PBTC, and the Department of Defense-funded Neurofibromatosis Clinical Consortium.

The PBTC is the premiere national multidisciplinary cooperative research group developing new therapies for CNS tumors of childhood. It has a highly competitive application process, which makes Cincinnati Children’s one of only 11 participating centers. In addition, Maryam Fouladi, MD, MSc, Professor of Pediatrics and Medical Director of Neuro-Oncology, has been elected to serve as national chair of the PBTC.

Experimental Hematology and Cancer Biology

Humoral and paracrine signals from the bone marrow hematopoietic microenvironment control blood generating stem cell activity during regenerative hematopoiesis. A group led by Jose Cancelas, MD, PhD, reported in Proceedings of the National Academy of Sciences, USA, that Connexin-43, a molecule involved in cell-cell communications, exerts a protective role and regulates the blood producing progenitor cell reactive oxygen species content through ROS transfer to the bone marrow microenvironment. This effect results in blood stem cell protection during stress hematopoietic regeneration under chemo or radiation therapies.

Tissue damage induced by ionizing radiation in the hematopoietic and gastrointestinal systems is the major cause of lethality in radiological emergency scenarios and underlies some deleterious side effects in children undergoing radiation therapy. The identification of target-specific interventions that confer radiomitigating activity is an unmet challenge. Hartmut Geiger, PhD, in collaboration with several other researchers at Cincinnati Children’s, Wisconsin and Arkansas, identified the thrombomodulin (Thbd)-activated protein C (aPC) pathway as a new mechanism for the mitigation of total body irradiation-induced mortality. Reporting in the journal Nature Medicine, they show that pharmacologic augmentation of the activity of the Thbd-aPC pathway by recombinant Thbd or aPC might offer a rational approach to the mitigation of tissue injury and lethality caused by ionizing radiation.

Small molecule targeted therapy has been hindered by an issue of druggability of target molecules. In a study published in Chemistry and Biology, Yi Zheng, PhD, led a group of chemical biologists to devise a novel approach of rational design of chemical compounds that selectively bind to and inhibit RhoA GTPase, a critical cell signal transducer with a globular structure involved in cancer cell proliferation and neuronal disorders. Their discovery suggests that design and search for low affinity binding chemicals tethered by proper linkers may be useful for rational targeting of “undruggable” biological molecules.

Hematology Division

The Hematology Division offers state-of-the-art testing for a variety of complex hematological diagnoses. Over the last year, the Sickle Cell Center, in collaboration with Human Genetics, has launched a genetics-based hemoglobinopathy diagnostic service, making Cincinnati Children’s one of only a few centers in the US that offer comprehensive genetic testing for hemoglobinopathies. Our Special Hemostasis Laboratory has expanded our repertoire of diagnostic studies available for the diagnosis and management of children with bleeding and thrombotic disorders. We recently added several new tests for the detailed diagnosis and characterization of Von Willebrand disease, the most common bleeding disorder in children, making us the only facility in the region offering these assays. We have also added several new tests for the evaluation of platelet function abnormalities, making our laboratory one of the few laboratories nationally with the capability to diagnose children with platelet disorders.


Division Publications

  1. Akbar H, Shang X, Perveen R, Berryman M, Funk K, Johnson JF, Tandon NN, Zheng Y. Gene targeting implicates Cdc42 GTPase in GPVI and non-GPVI mediated platelet filopodia formation, secretion and aggregation. PLoS One. 2011; 6:e22117.
  2. Ali AM, Pradhan A, Singh TR, Du C, Li J, Wahengbam K, Grassman E, Auerbach AD, Pang Q, Meetei AR. FAAP20: a novel ubiquitin-binding FA nuclear core complex protein required for functional integrity of the FA-BRCA DNA repair pathway. Blood. 2012; 119:3285-94.
  3. Bhatia S, Davies SM, Scott Baker K, Pulsipher MA, Hansen JA. NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: etiology and pathogenesis of late effects after HCT performed in childhood--methodologic challenges. Biol Blood Marrow Transplant. 2011; 17:1428-35.
  4. Bindels EM, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, Krivtsov AV, Rombouts E, Armstrong SA, Taskesen E, Haanstra JR, Beverloo HB, Dohner H, Hudson WA, Kersey JH, Delwel R, Kumar AR. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood. 2012; 119:5838-49.
  5. Bosco EE, Kumar S, Marchioni F, Biesiada J, Kordos M, Szczur K, Meller J, Seibel W, Mizrahi A, Pick E, Filippi MD, Zheng Y. Rational design of small molecule inhibitors targeting the Rac GTPase-p67(phox) signaling axis in inflammation. Chem Biol. 2012; 19:228-42.
  6. Cancelas JA. Adhesion, migration, and homing of murine hematopoietic stem cells and progenitors. Methods Mol Biol. 2011; 750:187-96.
  7. Cancelas JA. On how Rac controls hematopoietic stem cell activity. Transfusion. 2011; 51 Suppl 4:153S-159S.
  8. Cancelas JA, Rugg N, Fletcher D, Pratt PG, Worsham DN, Dunn SK, Marschner S, Reddy HL, Goodrich RP. In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood. Transfusion. 2011; 51:1460-8.
  9. Cancelas JA, Rugg N, Pratt PG, Worsham DN, Pehta JC, Banks K, Davenport RD, Judd WJ. Infusion of P-Capt prion-filtered red blood cell products demonstrate acceptable in vivo viability and no evidence of neoantigen formation. Transfusion. 2011; 51:2228-36.
  10. Carpenter PA, Meshinchi S, Davies SM. Transplantation for AML in children. Biol Blood Marrow Transplant. 2012; 18:S33-9.
  11. Chauhan BK, Lou M, Zheng Y, Lang RA. Balanced Rac1 and RhoA activities regulate cell shape and drive invagination morphogenesis in epithelia. Proc Natl Acad Sci U S A. 2011; 108:18289-94.
  12. Chen W, Wagner L, Boyd T, Nagarajan R, Dasgupta R. Extralobar pulmonary sequestration presenting with torsion: a case report and review of literature. J Pediatr Surg. 2011; 46:2025-8.
  13. Chernoguz A, Crawford K, Donovan E, Vandersall A, Berglund C, Cripe TP, Frischer JS. EGFR inhibition fails to suppress vascular proliferation and tumor growth in a Ewing's sarcoma model. J Surg Res. 2012; 173:1-9.
  14. Chow LM, Baker SJ. Capturing the molecular and biological diversity of high-grade astrocytoma in genetically engineered mouse models. Oncotarget. 2012; 3:67-77.
  15. Davies SM. Getting to the heart of the matter. J Clin Oncol. 2012; 30:1399-400.
  16. Davies SM, Levine JE. The 2012 education supplement on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012; 18:S1.
  17. DeBaun MR, Sarnaik SA, Rodeghier MJ, Minniti CP, Howard TH, Iyer RV, Inusa B, Telfer PT, Kirby-Allen M, Quinn CT, Bernaudin F, Airewele G, Woods GM, Panepinto JA, Fuh B, Kwiatkowski JK, King AA, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Sabio H, Gonzalez CE, Saccente SL, Kalinyak KA, Strouse JJ, Fixler JM, Gordon MO, Miller JP, Noetzel MJ, Ichord RN, Casella JF. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood. 2012; 119:3684-90.
  18. Degen JL, Palumbo JS. Hemostatic factors, innate immunity and malignancy. Thromb Res. 2012; 129 Suppl 1:S1-5.
  19. Dietz DM, Sun H, Lobo MK, Cahill ME, Chadwick B, Gao V, Koo JW, Mazei-Robison MS, Dias C, Maze I, Damez-Werno D, Dietz KC, Scobie KN, Ferguson D, Christoffel D, Ohnishi Y, Hodes GE, Zheng Y, Neve RL, Hahn KM, Russo SJ, Nestler EJ. Rac1 is essential in cocaine-induced structural plasticity of nucleus accumbens neurons. Nat Neurosci. 2012; 15:891-896.
  20. Dorris K, Fouladi M, Davies SM, Perentesis JP, Lawrence JM, Chow LM, Assa'ad A, Uygungil B, Jodele S. Severe allergic reactions to thiol-based cytoprotective agents mesna and amifostine in a child with a supratentorial primitive neuroectodermal tumor. J Pediatr Hematol Oncol. 2011; 33:e250-2.
  21. Drissi R, Wu J, Hu Y, Bockhold C, Dome JS. Telomere shortening alters the kinetics of the DNA damage response after ionizing radiation in human cells. Cancer Prev Res (Phila). 2011; 4:1973-81.
  22. Du W, Rani R, Sipple J, Schick J, Myers KC, Mehta P, Andreassen PR, Davies SM, Pang Q. The FA pathway counteracts oxidative stress through selective protection of antioxidant defense gene promoters. Blood. 2012; 119:4142-51.
  23. Dvorak CC, Bollard CM, El-Bietar J, Filipovich A. Complications of transplant for nonmalignant disorders: autoimmune cytopenias, opportunistic infections, and PTLD. Biol Blood Marrow Transplant. 2012; 18:S101-10.
  24. Elmeliegy MA, Carcaboso AM, LM LC, Zhang ZM, Calabrese C, Throm SL, Wang F, Baker SJ, Stewart CF. Magnetic resonance imaging-guided microdialysis cannula implantation in a spontaneous high-grade glioma murine model. J Pharm Sci. 2011; 100:4210-4214.
  25. Eshelman-Kent D, Kinahan KE, Hobbie W, Landier W, Teal S, Friedman D, Nagarajan R, Freyer DR. Cancer survivorship practices, services, and delivery: a report from the Children's Oncology Group (COG) nursing discipline, adolescent/young adult, and late effects committees. J Cancer Surviv. 2011; 5:345-57.
  26. Fadell MF, 2nd, Jones BV, Adams DM. Prenatal diagnosis and postnatal follow-up of rapidly involuting congenital hemangioma (RICH). Pediatr Radiol. 2011; 41:1057-60.
  27. Fang J, Varney M, Starczynowski DT. Implication of microRNAs in the Pathogenesis of MDS. Curr Pharm Des. 2012; 18:3170-9.
  28. Fernandes JF, Rocha V, Labopin M, Neven B, Moshous D, Gennery AR, Friedrich W, Porta F, Diaz de Heredia C, Wall D, Bertrand Y, Veys P, Slatter M, Schulz A, Chan KW, Grimley M, Ayas M, Gungor T, Ebell W, Bonfim C, Kalwak K, Taupin P, Blanche S, Gaspar HB, Landais P, Fischer A, Gluckman E, Cavazzana-Calvo M. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood?. Blood. 2012; 119:2949-55.
  29. Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, Liu GT. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012; 14:790-7.
  30. Florian MC, Dorr K, Niebel A, Daria D, Schrezenmeier H, Rojewski M, Filippi MD, Hasenberg A, Gunzer M, Scharffetter-Kochanek K, Zheng Y, Geiger H. Cdc42 activity regulates hematopoietic stem cell aging and rejuvenation. Cell Stem Cell. 2012; 10:520-30.
  31. Fouladi M, Stewart CF, Olson J, Wagner LM, Onar-Thomas A, Kocak M, Packer RJ, Goldman S, Gururangan S, Gajjar A, Demuth T, Kun LE, Boyett JM, Gilbertson RJ. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol. 2011; 29:3529-34.
  32. Franz DN, Weiss BD. Molecular therapies for tuberous sclerosis and neurofibromatosis. Curr Neurol Neurosci Rep. 2012; 12:294-301.
  33. Gamis AS, Alonzo TA, Gerbing RB, Hilden JM, Sorrell AD, Sharma M, Loew TW, Arceci RJ, Barnard D, Doyle J, Massey G, Perentesis J, Ravindranath Y, Taub J, Smith FO. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood. 2011; 118:6752-9; quiz 6996.
  34. Geh E, Meng Q, Mongan M, Wang J, Takatori A, Zheng Y, Puga A, Lang RA, Xia Y. Mitogen-activated protein kinase kinase kinase 1 (MAP3K1) integrates developmental signals for eyelid closure. Proc Natl Acad Sci U S A. 2011; 108:17349-54.
  35. Geiger H, Pawar SA, Kerschen EJ, Nattamai KJ, Hernandez I, Liang HP, Fernandez JA, Cancelas JA, Ryan MA, Kustikova O, Schambach A, Fu Q, Wang J, Fink LM, Petersen KU, Zhou D, Griffin JH, Baum C, Weiler H, Hauer-Jensen M. Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. Nat Med. 2012; 18:1123-1129.
  36. George A, Benton J, Pratt J, Kim MO, Kalinyak KA, Kalfa TA, Joiner CH. The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease. Pediatr Blood Cancer. 2011; 57:648-53.
  37. Goldsmith JC, Bonham VL, Joiner CH, Kato GJ, Noonan AS, Steinberg MH. Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications. Am J Hematol. 2012; 87:340-6.
  38. Goyama S, Mulloy JC. Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects. Int J Hematol. 2011; 94:126-33.
  39. Gruppo RA. (2011) Managing Atypical Hemolytic-Uremic Syndrome: What does the Future Hold?. Medscape Education. .
  40. Haggstrom AN, Beaumont JL, Lai JS, Adams DM, Drolet BA, Frieden IJ, Garzon MC, Holland KE, Horii KA, Lucky AW, Mancini AJ, Metry DW, Morel KD, Newell BD, Nopper AJ, Siegel D, Swigonski NL, Cella D, Chamlin SL. Measuring the severity of infantile hemangiomas: instrument development and reliability. Arch Dermatol. 2012; 148:197-202.
  41. Haines HL, Laskin BL, Goebel J, Davies SM, Yin HJ, Lawrence J, Mehta PA, Bleesing JJ, Filipovich AH, Marsh RA, Jodele S. Blood, and not urine, BK viral load predicts renal outcome in children with hemorrhagic cystitis following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011; 17:1512-9.
  42. Hammill AM, Wentzel M, Gupta A, Nelson S, Lucky A, Elluru R, Dasgupta R, Azizkhan RG, Adams DM. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011; 57:1018-24.
  43. Hines J, Mitchell M, Crosby L, Johnson A, Valenzuela J, Kalinyak K, Joiner C. Engaging Patients With Sickle Cell Disease and Their Families in Disease Education, Research, and Community Awareness. Journal of Prevention & Intervention in the Community. 2011; 39:256-272.
  44. Hines J, Mitchell MJ, Crosby LE, Johnson A, Valenzuela JM, Kalinyak K, Joiner C. Engaging patients with sickle cell disease and their families in disease education, research, and community awareness. Journal of Prevention and Intervention in the Community . 2011; 39:256-72.
  45. Hochman M, Adams DM, Reeves TD. Current knowledge and management of vascular anomalies, II: malformations. Arch Facial Plast Surg. 2011; 13:425-33.
  46. Horowitz NA, Blevins EA, Miller WM, Perry AR, Talmage KE, Mullins ES, Flick MJ, Queiroz KC, Shi K, Spek CA, Conway EM, Monia BP, Weiler H, Degen JL, Palumbo JS. Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood. 2011; 118:2889-95.
  47. Horowitz NA, Palumbo JS. PL-25 Mechanisms coupling thrombomodulin to tumor dissemination. Thromb Res. 2012; 129 Suppl 1:S119-21.
  48. Hoskins EE, Morreale RJ, Werner SP, Higginbotham JM, Laimins LA, Lambert PF, Brown DR, Gillison ML, Nuovo GJ, Witte DP, Kim MO, Davies SM, Mehta PA, Kovacic MB, Wikenheiser-Brokamp KA, Wells SI. The Fanconi Anemia Pathway Limits Human Papillomavirus Replication. J Virol. 2012; 86:8131-8.
  49. Huang G, Zhao X, Wang L, Elf S, Xu H, Zhao X, Sashida G, Zhang Y, Liu Y, Lee J, Menendez S, Yang Y, Yan X, Zhang P, Tenen DG, Osato M, Hsieh JJ, Nimer SD. The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. Blood. 2011; 118:6544-52.
  50. Jodele S, Bleesing JJ, Mehta PA, Filipovich AH, Laskin BL, Goebel J, Pinkard SL, Davies SM. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2012; 16:E39-42.
  51. Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011; 118:4041-52.
  52. Kaimal V, Chu Z, Mahller YY, Papahadjopoulos-Sternberg B, Cripe TP, Holland SK, Qi X. Saposin C Coupled Lipid Nanovesicles Enable Cancer-Selective Optical and Magnetic Resonance Imaging. Mol Imaging Biol. 2011; 13:886-897.
  53. Kalamarides M, Acosta MT, Babovic-Vuksanovic D, Carpen O, Cichowski K, Evans DG, Giancotti F, Hanemann CO, Ingram D, Lloyd AC, Mayes DA, Messiaen L, Morrison H, North K, Packer R, Pan D, Stemmer-Rachamimov A, Upadhyaya M, Viskochil D, Wallace MR, Hunter-Schaedle K, Ratner N. Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting. Acta Neuropathol. 2012; 123:369-80.
  54. Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Schwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM, Drissi R, Bissler JJ, Stambrook PJ, Andreassen PR, Wiesmuller L, Wells SI. The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res. 2011; 39:7465-76.
  55. Knapke S, Nagarajan R, Correll J, Kent D, Burns K. Hereditary cancer risk assessment in a pediatric oncology follow-up clinic. Pediatr Blood Cancer. 2012; 58:85-9.
  56. Kohler A, Geiger H, Gunzer M. Imaging hematopoietic stem cells in the marrow of long bones in vivo. Methods Mol Biol. 2011; 750:215-24.
  57. Komurov K. Modeling community-wide molecular networks of multicellular systems. Bioinformatics. 2012; 28:694-700.
  58. Konstantinidis DG, Pushkaran S, Johnson JF, Cancelas JA, Manganaris S, Harris CE, Williams DA, Zheng Y, Kalfa TA. Signaling and cytoskeletal requirements in erythroblast enucleation. Blood. 2012; 119:6118-27.
  59. Kuchenbauer F, Mah SM, Heuser M, McPherson A, Ruschmann J, Rouhi A, Berg T, Bullinger L, Argiropoulos B, Morin RD, Lai D, Starczynowski DT, Karsan A, Eaves CJ, Watahiki A, Wang Y, Aparicio SA, Ganser A, Krauter J, Dohner H, Dohner K, Marra MA, Camargo FD, Palmqvist L, Buske C, Humphries RK. Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. Blood. 2011; 118:3350-8.
  60. Kuras Z, Kucher V, Gordon SM, Neumeier L, Chimote AA, Filipovich AH, Conforti L. Modulation of K(V)1.3 channels by protein kinase A I in T lymphocytes is mediated by the disc large 1-tyrosine kinase Lck complex. Am J Physiol Cell Physiol. 2012; 302:C1504-12.
  61. Kurth M, Puetz J, Kouides P, Sanders J, Sexauer C, Bernstein J, Gruppo R, Manco-Johnson M, Neufeld EJ, Rodriguez N, Wicklund B, Quon D, Aledort L. The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience. J Thromb Haemost. 2011; 9:2229-34.
  62. Kwiatkowski JL, Kim HY, Thompson AA, Quinn CT, Mueller BU, Odame I, Giardina PJ, Vichinsky EP, Boudreaux JM, Cohen AR, Porter JB, Coates T, Olivieri NF, Neufeld EJ. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood. 2012; 119:2746-53.
  63. Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood. 2011; 118:1452-62.
  64. Leslie JR, Imai F, Zhou X, Lang RA, Zheng Y, Yoshida Y. RhoA is dispensable for axon guidance of sensory neurons in the mouse dorsal root ganglia. Front Mol Neurosci. 2012; 5:67.
  65. Levantini E, Lee S, Radomska HS, Hetherington CJ, Alberich-Jorda M, Amabile G, Zhang P, Gonzalez DA, Zhang J, Basseres DS, Wilson NK, Koschmieder S, Huang G, Zhang DE, Ebralidze AK, Bonifer C, Okuno Y, Gottgens B, Tenen DG. RUNX1 regulates the CD34 gene in haematopoietic stem cells by mediating interactions with a distal regulatory element. EMBO J. 2011; 30:4059-70.
  66. Li X, Sipple J, Pang Q, Du W. Salidroside stimulates DNA repair enzyme Parp-1 activity in mouse HSC maintenance. Blood. 2012; 119:4162-73.
  67. Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, Hyjek E, Zhang J, Zhang Z, Elkahloun A, Cao D, Shen C, Wunderlich M, Wang Y, Neilly MB, Jin J, Wei M, Lu J, Valk PJ, Delwel R, Lowenberg B, Le Beau MM, Vardiman J, Mulloy JC, Zeleznik-Le NJ, Liu PP, Zhang J, Chen J. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun. 2012; 3:688.
  68. Liu M, Bi F, Zhou X, Zheng Y. Rho GTPase regulation by miRNAs and covalent modifications. Trends Cell Biol. 2012; 22:365-73.
  69. Liu M, Tang Q, Qiu M, Lang N, Li M, Zheng Y, Bi F. miR-21 targets the tumor suppressor RhoB and regulates proliferation, invasion and apoptosis in colorectal cancer cells. FEBS Lett. 2011; 585:2998-3005.
  70. Liu W, Feng Y, Shang X, Zheng Y. Rho GTPases in hematopoietic stem/progenitor cell migration. Methods Mol Biol. 2011; 750:307-19.
  71. Maddala R, Chauhan BK, Walker C, Zheng Y, Robinson ML, Lang RA, Rao PV. Rac1 GTPase-deficient mouse lens exhibits defects in shape, suture formation, fiber cell migration and survival. Dev Biol. 2011; 360:30-43.
  72. Maiques-Diaz A, Chou FS, Wunderlich M, Gomez-Lopez G, Jacinto FV, Rodriguez-Perales S, Larrayoz MJ, Calasanz MJ, Mulloy JC, Cigudosa JC, Alvarez S. Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs. Leukemia. 2012; 26:1329-37.
  73. Marsh RA, Filipovich AH. Familial hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease. Ann N Y Acad Sci. 2011; 1238:106-21.
  74. Marsh RA, Jordan MB, Filipovich AH. Reduced-intensity conditioning haematopoietic cell transplantation for haemophagocytic lymphohistiocytosis: an important step forward. Br J Haematol. 2011; 154:556-63.
  75. Maugans T, Sheridan RM, Adams D, Gupta A. Cutaneous vascular anomalies associated with neural tube defects: nomenclature and pathology revisited. Neurosurgery. 2011; 69:112-8; discussion 118.
  76. Mayes DA, Rizvi TA, Cancelas JA, Kolasinski NT, Ciraolo GM, Stemmer-Rachamimov AO, Ratner N. Perinatal or adult Nf1 inactivation using tamoxifen-inducible PlpCre each cause neurofibroma formation. Cancer Res. 2011; 71:4675-85.
  77. McCarville MB, Rogers ZR, Sarnaik S, Scott P, Aygun B, Hilliard L, Lee MT, Kalinyak K, Owen W, Garro J, Schultz W, Yovetich N, Ware RE, Investigators SW. Effects of chronic transfusions on abdominal sonographic abnormalities in children with sickle cell anemia. J Pediatr. 2012; 160:281-285 e1.
  78. McCavit TL, Xuan L, Zhang S, Flores G, Quinn CT. Hospitalization for invasive pneumococcal disease in a national sample of children with sickle cell disease before and after PCV7 licensure. Pediatr Blood Cancer. 2012; 58:945-9.
  79. Meyer A, Wang W, Qu J, Croft L, Degen JL, Coller BS, Ahamed J. Platelet TGF-beta1 contributions to plasma TGF-beta1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload. Blood. 2012; 119:1064-74.
  80. Meyers AB, Towbin AJ, Serai S, Geller JI, Podberesky DJ. Characterization of pediatric liver lesions with gadoxetate disodium. Pediatr Radiol. 2011; 41:1183-97.
  81. Mizukawa B, Wei J, Shrestha M, Wunderlich M, Chou FS, Griesinger A, Harris CE, Kumar AR, Zheng Y, Williams DA, Mulloy JC. Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia. Blood. 2011; 118:5235-45.
  82. Montes de Oca R, Andreassen PR, Wilson KL. Barrier-to-Autointegration Factor influences specific histone modifications. Nucleus. 2011; 2:580-90.
  83. Morris CR, Kim HY, Trachtenberg F, Wood J, Quinn CT, Sweeters N, Kwiatkowski JL, Thompson AA, Giardina PJ, Boudreaux J, Olivieri NF, Porter JB, Neufeld EJ, Vichinsky EP. Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. Blood. 2011; 118:3794-802.
  84. Morrison MA, Morreale RJ, Akunuru S, Kofron M, Zheng Y, Wells SI. Targeting the human papillomavirus E6 and E7 oncogenes through expression of the bovine papillomavirus type 1 E2 protein stimulates cellular motility. J Virol. 2011; 85:10487-98.
  85. Muller LU, Milsom MD, Harris CE, Vyas R, Brumme KM, Parmar K, Moreau LA, Schambach A, Park IH, London WB, Strait K, Schlaeger T, Devine AL, Grassman E, D'Andrea A, Daley GQ, Williams DA. Overcoming reprogramming resistance of Fanconi anemia cells. Blood. 2012; 119:5449-57.
  86. Myers K, Davies SM, Harris RE, Spunt SL, Smolarek T, Zimmerman S, McMasters R, Wagner L, Mueller R, Auerbach AD, Mehta PA. The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations. Pediatr Blood Cancer. 2012; 58:462-5.
  87. Myers KC, Bleesing JJ, Davies SM, Zhang X, Martin LJ, Mueller R, Harris RE, Filipovich AH, Kovacic MB, Wells SI, Mehta PA. Impaired immune function in children with Fanconi anaemia. Br J Haematol. 2011; 154:234-40.
  88. Navarro-Lerida I, Sanchez-Perales S, Calvo M, Rentero C, Zheng Y, Enrich C, Del Pozo MA. A palmitoylation switch mechanism regulates Rac1 function and membrane organization. EMBO J. 2012; 31:534-51.
  89. Nawrot M, McKenna DH, Sumstad D, McMannis JD, Szczepiorkowski ZM, Belfield H, Grassman E, Temples T, Nielsen D, Yuan N, Wognum B, Reems JA. Interlaboratory assessment of a novel colony-forming unit assay: a multicenter study by the cellular team of Biomedical Excellence for Safer Transfusion (BEST) collaborative. Transfusion. 2011; 51:2001-5.
  90. Negrotto S, Ng KP, Jankowska AM, Bodo J, Gopalan B, Guinta K, Mulloy JC, Hsi E, Maciejewski J, Saunthararajah Y. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia. 2012; 26:244-54.
  91. Nemecek ER, Ellis K, He W, Bunin NJ, Bajwa RS, Cheerva A, Cairo MS, Dvorak C, Duval M, Davies S, Eapen M, Gross TG, Hussein AA, MacMillan ML, Mehta PA, Pulsipher MA, Seber A, Woolfrey AE, Frangoul HA, Carpenter PA. Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission. Biol Blood Marrow Transplant. 2011; 17:1833-40.
  92. Ng KP, Ebrahem Q, Negrotto S, Mahfouz RZ, Link KA, Hu Z, Gu X, Advani A, Kalaycio M, Sobecks R, Sekeres M, Copelan E, Radivoyevitch T, Maciejewski J, Mulloy JC, Saunthararajah Y. p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia. 2011; 25:1739-50.
  93. Pan D, Kalfa TA, Wang D, Risinger M, Crable S, Ottlinger A, Chandra S, Mount DB, Hubner CA, Franco RS, Joiner CH. K-Cl Cotransporter Gene Expression during Human and Murine Erythroid Differentiation. J Biol Chem. 2011; 286:30492-503.
  94. Pennarola BW, Rodday AM, Mayer DK, Ratichek SJ, Davies SM, Syrjala KL, Patel S, Bingen K, Kupst MJ, Schwartz L, Guinan EC, Hibbard JH, Parsons SK. Factors associated with parental activation in pediatric hematopoietic stem cell transplant. Med Care Res Rev. 2012; 69:194-214.
  95. Phillips CL, Miles L, Jones BV, Sutton M, Crone K, Fouladi M. Medulloblastoma with melanotic differentiation: case report and review of the literature. J Neurooncol. 2011; 103:759-64.
  96. Plageman TF, Jr., Chauhan BK, Yang C, Jaudon F, Shang X, Zheng Y, Lou M, Debant A, Hildebrand JD, Lang RA. A Trio-RhoA-Shroom3 pathway is required for apical constriction and epithelial invagination. Development. 2011; 138:5177-88.
  97. Qi X, Flick MJ, Frederick M, Chu Z, Mason R, DeLay M, Thornton S. Saposin C coupled lipid nanovesicles specifically target arthritic mouse joints for optical imaging of disease severity. PLoS One. 2012; 7:e33966.
  98. Quarmyne MO, Risinger M, Linkugel A, Frazier A, Joiner C. Volume regulation and KCl cotransport in reticulocyte populations of sickle and normal red blood cells. Blood Cells Mol Dis. 2011; 47:95-9.
  99. Quinn CT, Stuart MJ, Kesler K, Ataga KI, Wang WC, Styles L, Smith-Whitley K, Wun T, Raj A, Hsu LL, Krishnan S, Kuypers FA, Setty Y, Rhee S, Key NS, Buchanan GR. Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. Br J Haematol. 2011; 155:263-7.
  100. Raghu H, Flick MJ. Targeting the coagulation factor fibrinogen for arthritis therapy. Curr Pharm Biotechnol. 2011; 12:1497-506.
  101. Rani R, Jordan MB, Divanovic S, Herbert DR. IFN-gamma-driven IDO production from macrophages protects IL-4Ralpha-deficient mice against lethality during Schistosoma mansoni infection. Am J Pathol. 2012; 180:2001-8.
  102. Rhyasen GW, Starczynowski DT. Deregulation of microRNAs in myelodysplastic syndrome. Leukemia. 2012; 26:13-22.
  103. Risma K, Jordan MB. Hemophagocytic lymphohistiocytosis: updates and evolving concepts. Curr Opin Pediatr. 2012; 24:9-15.
  104. Sam TN, Kersey JH, Linabery AM, Johnson KJ, Heerema NA, Hilden JM, Davies SM, Reaman GH, Ross JA. MLL gene rearrangements in infant leukemia vary with age at diagnosis and selected demographic factors: a Children's Oncology Group (COG) study. Pediatr Blood Cancer. 2012; 58:836-9.
  105. Sashida G, Bae N, Di Giandomenico S, Asai T, Gurvich N, Bazzoli E, Liu Y, Huang G, Zhao X, Menendez S, Nimer SD. The mef/elf4 transcription factor fine tunes the DNA damage response. Cancer Res. 2011; 71:4857-65.
  106. Sengupta A, Cancelas JA. A conundrum in mammalian hematopoietic stem cell polarity. Cell Cycle. 2011; 10:4191-2.
  107. Sengupta A, Ficker AM, Dunn SK, Madhu M, Cancelas JA. Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells. Blood. 2012; 119:494-502.
  108. Shang X, Cancelas JA, Li L, Guo F, Liu W, Johnson JF, Ficker A, Daria D, Geiger H, Ratner N, Zheng Y. R-Ras and Rac GTPase cross-talk regulates hematopoietic progenitor cell migration, homing, and mobilization. J Biol Chem. 2011; 286:24068-78.
  109. Shang X, Marchioni F, Sipes N, Evelyn CR, Jerabek-Willemsen M, Duhr S, Seibel W, Wortman M, Zheng Y. Rational Design of Small Molecule Inhibitors Targeting RhoA Subfamily Rho GTPases. Chem Biol. 2012; 19:699-710.
  110. Sharkawi E, Hamedani M, Fouladi M. Eyelid squamous cell carcinoma in situ treated with topical 5-fluorouracil. Clin Experiment Ophthalmol. 2011; 39:915-6.
  111. Sharp SE, Gelfand MJ, Absalon MJ. Altered FDG uptake patterns in pediatric lymphoblastic lymphoma patients receiving induction chemotherapy that includes very high dose corticosteroids. Pediatr Radiol. 2012; 42:331-6.
  112. Shin CR, Nathan J, Alonso M, Yazigi N, Kocoshis S, Tiao G, Davies SM. Incidence of acute and chronic graft-versus-host disease and donor T-cell chimerism after small bowel or combined organ transplantation. J Pediatr Surg. 2011; 46:1732-8.
  113. Singbartl K, Bishop JV, Wen X, Murugan R, Chandra S, Filippi MD, Kellum JA. Differential effects of kidney-lung cross-talk during acute kidney injury and bacterial pneumonia. Kidney Int. 2011; 80:633-44.
  114. Sipes NS, Feng Y, Guo F, Lee HO, Chou FS, Cheng J, Mulloy J, Zheng Y. Cdc42 regulates extracellular matrix remodeling in three dimensions. J Biol Chem. 2011; 286:36469-77.
  115. Sorensen I, Susnik N, Inhester T, Degen JL, Melk A, Haller H, Schmitt R. Fibrinogen, acting as a mitogen for tubulointerstitial fibroblasts, promotes renal fibrosis. Kidney Int. 2011; 80:1035-44.
  116. Starczynowski DT, Lockwood WW, Delehouzee S, Chari R, Wegrzyn J, Fuller M, Tsao MS, Lam S, Gazdar AF, Lam WL, Karsan A. TRAF6 is an amplified oncogene bridging the RAS and NF-kappaB pathways in human lung cancer. J Clin Invest. 2011; 121:4095-105.
  117. Stengel K, Zheng Y. Cdc42 in oncogenic transformation, invasion, and tumorigenesis. Cell Signal. 2011; 23:1415-23.
  118. Stengel KR, Zheng Y. Essential role of cdc42 in ras-induced transformation revealed by gene targeting. PLoS One. 2012; 7:e37317.
  119. Sullivan BP, Kassel KM, Jone A, Flick MJ, Luyendyk JP. Fibrin(ogen)-Independent Role of Plasminogen Activators in Acetaminophen-Induced Liver Injury. Am J Pathol. 2012; 180:2321-9.
  120. Sundaram N, Bennett M, Wilhelm J, Kim MO, Atweh G, Devarajan P, Malik P. Biomarkers for early detection of sickle nephropathy. Am J Hematol. 2011; 86:559-66.
  121. Tan Z, Wortman M, Dillehay KL, Seibel WL, Evelyn CR, Smith SJ, Malkas LH, Zheng Y, Lu S, Dong Z. Small Molecule Targeting of PCNA Chromatin Association Inhibits Tumor Cell Growth. Mol Pharmacol. 2012; 81:811-9.
  122. Taniguchi Ishikawa E, Gonzalez-Nieto D, Ghiaur G, Dunn SK, Ficker AM, Murali B, Madhu M, Gutstein DE, Fishman GI, Barrio LC, Cancelas JA. Connexin-43 prevents hematopoietic stem cell senescence through transfer of reactive oxygen species to bone marrow stromal cells. Proc Natl Acad Sci U S A. 2012; 109:9071-6.
  123. Tolar J, Mehta PA, Walters MC. Hematopoietic cell transplantation for nonmalignant disorders. Biol Blood Marrow Transplant. 2012; 18:S166-71.
  124. Trottestam H, Horne A, Arico M, Egeler RM, Filipovich AH, Gadner H, Imashuku S, Ladisch S, Webb D, Janka G, Henter JI. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011; 118:4577-84.
  125. van der Loo JC, Swaney WP, Grassman E, Terwilliger A, Higashimoto T, Schambach A, Baum C, Thrasher AJ, Williams DA, Nordling DL, Reeves L, Malik P. Scale-up and manufacturing of clinical-grade self-inactivating gamma-retroviral vectors by transient transfection. Gene Ther. 2012; 19:246-54.
  126. Veys P, Wynn RF, Ahn KW, Samarasinghe S, He W, Bonney D, Craddock J, Cornish J, Davies SM, Dvorak CC, Duerst RE, Gross TG, Kapoor N, Kitko C, Krance RA, Leung W, Lewis VA, Steward C, Wagner JE, Carpenter PA, Eapen M. Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia. Blood. 2012; 119:6155-61.
  127. Vidal B, Ardite E, Suelves M, Ruiz-Bonilla V, Janue A, Flick MJ, Degen JL, Serrano AL, Munoz-Canoves P. Amelioration of Duchenne muscular dystrophy in mdx mice by elimination of matrix-associated fibrin-driven inflammation coupled to the alphaMbeta2 leukocyte integrin receptor. Hum Mol Genet. 2012; 21:1989-2004.
  128. Wagner LM, Smolarek TA, Sumegi J, Marmer D. Assessment of minimal residual disease in ewing sarcoma. Sarcoma. 2012; 2012:780129.
  129. Wang J, Geiger H, Rudolph KL. Immunoaging induced by hematopoietic stem cell aging. Curr Opin Immunol. 2011; 23:532-6.
  130. Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G, Hatlen MA, Vu L, Liu F, Xu H, Asai T, Deblasio T, Menendez S, Voza F, Jiang Y, Cole PA, Zhang J, Melnick A, Roeder RG, Nimer SD. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science. 2011; 333:765-9.
  131. Wang PS, Wang J, Zheng Y, Pallen CJ. Loss of Protein-tyrosine Phosphatase alpha (PTPalpha) Increases Proliferation and Delays Maturation of Oligodendrocyte Progenitor Cells. J Biol Chem. 2012; 287:12529-40.
  132. Wani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison D, Gilbertson R, Vaillant B, Goldman S, Packer RJ, Fouladi M, Pollack I, Mikkelsen T, Prados M, Omuro A, Soffietti R, Ledoux A, Wilson C, Long L, Gilbert MR, Aldape K. A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol. 2012; 123:727-38.
  133. Weiss BD, Dasgupta R, Gelfand MJ, Laor T, Yin H, Breneman JC, Lavigne R, Elluru RG, Wagner LM. Use of sentinel node biopsy for staging parameningeal rhabdomyosarcoma. Pediatr Blood Cancer. 2011; 57:520-3.
  134. Wood M, Rawe M, Johansson G, Pang S, Soderquist RS, Patel AV, Nelson S, Seibel W, Ratner N, Sanchez Y. Discovery of a Small Molecule Targeting IRA2 Deletion in Budding Yeast and Neurofibromin Loss in Malignant Peripheral Nerve Sheath Tumor Cells. Mol Cancer Ther. 2011; 10:1740-50.
  135. Wu J, Dombi E, Jousma E, Scott Dunn R, Lindquist D, Schnell BM, Kim MO, Kim A, Widemann BC, Cripe TP, Ratner N. Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatr Blood Cancer. 2012; 58:173-80.
  136. Xiang SY, Vanhoutte D, Del Re DP, Purcell NH, Ling H, Banerjee I, Bossuyt J, Lang RA, Zheng Y, Matkovich SJ, Miyamoto S, Molkentin JD, Dorn GW, 2nd, Brown JH. RhoA protects the mouse heart against ischemia/reperfusion injury. J Clin Invest. 2011; 121:3269-76.
  137. Yang J, Ylipaa A, Sun Y, Zheng H, Chen K, Nykter M, Trent J, Ratner N, Lev DC, Zhang W. Genomic and Molecular Characterization of Malignant Peripheral Nerve Sheath Tumor Identifies the IGF1R Pathway as a Primary Target for Treatment. Clin Cancer Res. 2011; 17:7563-7573.
  138. Yoshimi M, Goyama S, Kawazu M, Nakagawa M, Ichikawa M, Imai Y, Kumano K, Asai T, Mulloy JC, Kraft AS, Takahashi T, Shirafuji N, Kurokawa M. Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation. Eur J Immunol. 2012; 42:1044-50.
  139. You J, Wells SI. Human Papillomaviruses and cancer. Cancer associated viruses. New York: Springer; 2012:463-487.
  140. You J, Wells SI. Human Papillomaviruses and Cancer. Cancer associated viruses. New York: Springer; 2011:463-487.
  141. Young G, Shapiro AD, Walsh CE, Gruppo RA, Gut RZ, Cooper DL. Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE). Haemophilia. 2012; 18:392-9.
  142. Zhang K, Jordan MB, Marsh RA, Johnson JA, Kissell D, Meller J, Villanueva J, Risma KA, Wei Q, Klein PS, Filipovich AH. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 2011; 118:5794-8.
  143. Zhang S, Zhou X, Lang RA, Guo F. RhoA of the Rho family small GTPases is essential for B lymphocyte development. PLoS One. 2012; 7:e33773.
  144. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, Bradner JE, Lowe SW, Vakoc CR. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011; 478:524-8.

Grants, Contracts, and Industry Agreements

Division Grants

Bone Marrow Transplantation and Immune Deficiency

Grant and Contract AwardsAnnual Direct

Davies, S

Antileukemic Effect of NK Cells in HCT for Pediatric AML
R01 CA 12058308/01/07-06/30/12$8,864
Childhood Cancer Survivor Study
U24 CA 05572712/01/11-11/30/16$177,391
Children's Oncology Chair Award
U10 CA 09854303/01/11-02/28/14$12,831
Multicenter Pilot Trial of HSCT Lacking a Genotype Identical Donor
05/01/10-04/30/13$1,160
Molecular Epidemiology of Pediatric Germ Cell Tumors
R01 CA15128408/10/11-05/31/16$21,219

Filipovich, A

Gene Therapy for SCID-X1 Using Self-Inactivating (SIN) Gammaretroviral Vector
U01 AI 08762809/01/10-08/31/15$121,927
Hypoxia and Potassium Channel Activity in T Lymphocytes
R01 CA 09528606/01/09-04/30/12$19,959
Rare Diseases Clinical Consortia for the Rare Diseases - Per Patient
U54 AI 08297309/12/09-08/31/14$60,333

Kumar, A

Molecular Pathogenesis of MLL-Fusion Gene Leukemia
K08 CA 12219108/19/09-06/30/12$125,250

Marsh, R

Studies to Determine Why ZIAP Deficiency Leads to HLH
07/01/10-06/30/12$85,000

Mehta, P

Quercetin in Patients with Fanconi Anemia, a Pilot Study
07/01/11-06/30/13$27,273

Sumegi, J

Biomarkers in Primary and Secondary Hemophagocytic Lymphohistiocytosis
01/01/12-12/31/12$50,000
Identification of PAX3-NCOA1/NCOA2-Regulated Genes in Rhabdomyosarcoma
01/01/12-12/31/12$8,000
Current Year Direct$719,207
Industry Contracts

Grimley, M

$86,647

Harris, R

$1,578
Current Year Direct Receipts$88,225
Service Collaborations

Joshi, S

$1,500
Current Year Direct$1,500
Funded Collaborative Efforts

Bleesing, J

NIAMS Multidisciplinary Clinical Research Center
Lovell, D08/18/08-07/30/133%

Davies, S

Nonadherence: Undermining Health Outcomes in Pediatric HSCT
Pai03/01/12-02/28/1710%
Total$808,932

Division Grants

Experimental Hematology

Grant and Contract AwardsAnnual Direct

Andreassen, P

FANCD2 Monoubiquitination in DNA Damage Responses
R01 HL 08558707/08/08-06/30/13$225,000

Azam, M

To Study the Molecular Mechanisms of "BCR/ABL Addiction" in Chronic Myeloid Leukemia
07/01/11-06/30/12$100,000
Mitogenic Activities in Neurofibromatosis
R01 CA15509105/01/12-03/31/17$207,500

Cancelas-Perez, J

Gap Junction Intercellular Communication in Bone Marrow
W81XWH111029604/01/11-09/30/12$33,063
Improving Stem Cell Mobilization by the EGFR Inhibitor Erlotinib
R34 HL 10840302/15/12-01/31/13$98,337
Rac GTPase Inhibition in Chronic Myelogenous Leukemia
R01 HL 08715904/06/09-02/28/13$247,500

Choi, K

Regulation of Cellular Growth and Differentiation
T32 CA 05926812/6/11-12/5/12$49,998

Degen, J

Analysis of Staphylococcus Aureus Host Interactions
R01 AI 02062409/30/10-08/31/12$51,239
Thrombin-Mediated Proteolysis in Neuroinflammatory Disease
R01 HL09612608/01/09-04/30/13$247,500

Degen, J / Malik P

Hemostatic Factors and Sickle Cell Disease
R01 HL 11260301/01/12-11/30/16$250,000

Filippi, M

Regulation of Hematopoietic Stem Cell Self Renewal
R21 HL 10445808/01/10-07/31/12$125,000
Regulation of Neutrophil Migration and Polarity
R01 HL 09067603/01/10-02/28/15$247,500

Flick, M

Mechanisms Linking the Hemostatic Protease Thrombin to Arthritic Disease
R01 AR 05699008/10/09-07/31/14$171,072
Digestive Health Center - Pilot & Feasibility Study
P30 DK 078392 (Bezerra)06/01/12-05/31/13$36,667

Geiger, H

Activated Protein C for Treatment of Radiation Combined Injury
R33 AI 08055709/13/10-08/31/13$79,070

Huang, G

Molecular Mechanisms of Leukemogenesis Mediated by MLL-Partial Tandem Duplication (MLL-PTD)
07/01/11-06/30/13$27,273
Targeting the "Warburg Effect" in Cancer
06/01/12-05/31/13$20,000

Link, K

Environmental Carcinogenesis and Mutagenesis
T32 ES 00725009/01/10-06/30/12$53,494

Malik, P

Ameliorating Sickle Nephropathy and Pulmonary Hypertension
R34 HL 10875208/18/11-06/30/14$150,000
Cincinnati Cell Characterization Core
U01 HL 09999709/01/10-04/30/13$354,674
Development of Safe and Efficient Gene Therapy Strategies
R01 HL 09848901/21/10-12/31/14$48,833
PIGF-HIF 1a-miRNA Axis in Sickle Pulmonary Hypertension
R01 HL11137201/01/12-12/31/16$161,480
Cincinnati Cell Characterization Core - Per assay
U01 HL 09999709/01/10-04/30/13$18,986
Cincinnati Center for Clinical/Translational Sciences & Training
UL1 RR 02631404/03/09-03/31/14$40,294

Meetei, R

Functional and Molecular Characterization of Two New Members of the Bloom Syndrome Complex
07/01/10-06/30/12$27,272

Mulloy, J

Next Generation DNMT-1 Depletion Therapy for Leukemia
W81XWH-09-1-067109/01/09-09/01/12$141,405
Novel Therapeutic Target in Leukemia Stem Cells
07/01/10-06/30/12$100,000
Rac Signaling in MLL Leukemia
07/01/10-06/30/15$104,762

Nassar, N

Ras, Cycling and Inhibition
R01 CA11561103/01/11-02/28/13$108,236

Olshavsky, N

Regulation of Cellular Growth and Differentiation
T32 CA5926812/06/10-12/05/12$32,303

Pan, D

Genetic Therapy for CNS Manifestations in MPS I via BBB-Targeted Protein Delivery
R01 NS 06433009/30/08-08/31/13$214,375

Pang, Q

Role of FA Proteins in Hematopoiesis
R01 HL 07671204/01/10-03/31/15$250,000
Role of Tumor Necrosis Factor in Leukemogenesis
07/01/08-06/30/13$103,115
Targeted Improvement in Stem Cell Therapy for Leukemia and Bone Marrow Failure Syndromes
R01 CA 15753702/01/11-12/31/15$207,500

Patel, A

Identification and study of Novel Genes Critical to survival of MPNSTS
W81XWH111014406/01/11-05/31/13$50,000

Ratner, N

Cincinnati Center for Neurofibromatosis Research
P50 NS 05753109/15/08-06/30/13$1,033,483
Ratner, NProject A$48,069
Cripe, TProject B$106,147
Rizvi, TProject C$81,328
Perentesis, JProject 1$297,055
Ratner, NProject 2$224,070
Ratner, NProject 3$276,814
$
Mitogenic Activities in Neurofibromatosis
R01 NS 02884009/15/11-07/31/16$231,250
Modelling Brain Defects in NF1
W81XWH101011604/01/10-03/31/13$251,091

Starczynowski, D

Deregulation of TIFAB in Myelodysplastic Syndrome
07/01/11-06/30/14$50,000
Regulation and Function of TIFAB in Myelodysplastic Syndrome
W81XWH111046806/01/11-05/31/14$132,295
Identification and Characterization of Genes in del(5q) Myelodysplastic Syndrome
R01 HL11110312/05/11-11/30/16$250,000

van der Loo, J

AKTA Ready Liquid Chromatography System
S10 RR 03172107/01/11-06/30/12$175,119

Varney, M

Environmental Carcinogenesis and Mutagenesis
T32 ES 00725005/01/12-04/30/14$49,198

Wu, J

STAT3 in Neurofibroma Tumorigenesis and Therapy
W81XWH111025907/01/11-06/30/14$129,364
STAT3 in Neurofibroma Tumorigenesis and Therapy
08/01/10-07/31/12$49,205

Zheng, Y/ Geiger, H

Lineage Determination and Tissue HomeOstasis in the Aged Hematopoietic System
R01 AG 04011808/01/11-07/31/16$225,000

Zheng, Y

Cincinnati Center for Excellence in Molecular Hematology
P30 DK 09097109/30/10-06/30/15$482,569
Zheng, YAdmin Core$89,909
Grabowsky, GGenomics and Genetics Core$63,000
Cancelas, JCell Analysis and Sorting Core$65,112
Malik, PTranslational Core$165,412
Mulloy, JXenotransplant and Transgenic Core$68,766
Zheng, YSummer Students$30,370
Rac GTPase-Specific Small Molecular Inhibitors
R01 CA 14134103/24/09-01/31/14$165,237
Training Program in Pediatric Hematologic and Oncologic Diseases
T32 HL 09180509/01/08-08/31/13$164,652
Rac GTPases in the Mammalian Brain Development
R01 NS 05643507/01/08-06/30/12$165,237

Zheng, Y / Mulloy J

Targeting Cdc42 in Leukemia Stem Cells
R01 CA 15054703/10/10-01/31/15$201,275
Current Year Direct$8,138,423
Industry Contracts

Flick, M

$53,159

Malik, P

$4,719

Mulloy, J

$63,229
Current Year Direct Receipts$121,107
Service Collaborations

Grassman, E

$183,361
$11,593
Current Year Direct$194,954
Funded Collaborative Efforts

Malik, P

Macrophage-based Human Gene Therapy for Hereditary PAP
Trapnell, B12/15/10-11/30/125%
Role of Anti-GM-CSF Antibodies in Myeloid Cell Function
Trapnell, B04/01/11-03/31/165%

Andreassen, P

DNA Damage Response Pathways in Meiotic Sex Chromosome Inactivation
Namekawa, F08/01/11-07/31/167.5%
Total$8,454,484

Division Grants

Hematology

Grant and Contract AwardsAnnual Direct

Gruppo, R

ATHNdata.Quality Counts
01/15/11-01/14/13$10,315
Hemophilia And Thrombosis Center
06/01/03-05/31/13$90,000
Hemophilia Comprehensive Care
H30MC0001506/01/04-05/31/12$14,500
Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting Disorders
U27 DD 00086209/30/11-09/29/14$17,000
Hemophilia Patient Handbook
05/01/2012-04/30/2013$5,000

Joiner, C

Cincinnati Sickle Cell Project
03130011SK041107/01/1998-06/30/2012$123,469

Kalfa, T

Rac1 and Rac2 Guanosine Triphosphatases in Erythroid Function and Differentiation
K08 HL 08812602/11/08-11/30/12$119,125

Mullins, E

Mechanisms Linking Hemostatic Factors to Neuroinflammatory Disease
K08 HL 10567208/22/11-07/31/16$121,375

Shook, L

Cincinnati Sickle Cell Newborn Screening Network
U38 MC 2221806/01/11-05/31/15$377,100
Sickle Cell Treatment Demonstration Program
U1EMC0755-0609/01/11-08/31/14$11,318
Current Year Direct$889,202
Industry Contracts

Gruppo, R

$25,987
$15,828
$34,798
$11,758
$2,434
$1,540

Kalfa, T

$6,884

Kalinyak, K

$6,545

Quinn, C

$26,488
$25,327

Palumbo, J

$86,375
Current Year Direct Receipts$243,964
Total$1,133,166

Division Grants

Oncology

Grant and Contract AwardsAnnual Direct

Adams, D

Phase II Study of Rapamycin for Complicated Vascular Anomalies
R01 FD 00371209/25/09-07/31/13$248,540

Chow, L

Micro-RNA Expression in Pediatric High-Grade Glioma
-08/01/11-07/31/12$40,000
Micro-RNA Expression in Pediatric High-Grade Glioma
-09/01/11-08/31/13$22,727
Molecular Targeting of High-Grade Astrocytoma
-10/01/11-09/30/15$130,435
Molecular Targeting of Pediatric High-Grade Glioma
07/01/11-06/30/14$110,000

Cripe, T

Neurofibromatosis Preclinical Consortium Center Award
2011-05-00307/01/11-06/30/13$136,364
Phase I Study of HSV1716 in Pediatric Non-CNS Solid Tumors
R01 FD 00371709/01/10-08/31/13$152,618
Acidic Phospholipid-Selective Treatment for Neuroblastoma
R01 CA 15837209/27/11-07/31/13$12,760

Dorris, K

Molecular Epidemiology in Children's Environmental Health
T32 ES01095710/01/10-09/30/12$52,293

Drissi, R

Biology Studies in the First Phase I Trial of a Telomerase Inhibitor in Children with Refractory or Recurrent Solid Tumors and Lymphomas
08/01/11-07/31/12$40,000

Fouladi, M

Children's Oncology Group Phase I / Pilot Consortium
U10 CA 09745209/16/11-07/31/12$25,662
Establishment of an International Diffuse Intrinsic Pontine Glioma (DIPG) Registry
01/01/12-12/31/12$155,000
The Pediatric Brain Tumor Consortium
U01 CA 08145704/01/08-03/31/13$93,908
Children's Oncology Group Chair
U10 CA 09854303/01/11-02/29/12$12,500

Hammill, A

Ontogeny and Quantitative Multimodal Skin Imaging of Infantile Hemangiomas
07/01/11-06/30/12$6,500

Perentesis, J

Children's Oncology Group Phase I
U01 CA 09745208/01/07-07/31/11$23,918
Children's Oncology Group Phase I / Pilot Consortium
U01 CA 09745209/01/06-07/31/12$26,124
Cincinnati Children’s Hyundai Scholar in Cancer Survivorship
10/01/11-12/01/12$100,000
Children's Oncology Group Phase I / Pilot Consortium - Per Patient
U01 CA 09745209/01/06-07/31/12$38,058
Children's Oncology Group Chair - Per Patient
U10 CA 09854303/01/11-02/28/12$57,840

Pope, J

Analysis of Antioxidant Polymorphisms in Patients with Down Syndrome and CML
07/01/10-06/30/12$70,804

Wang, P-Y

Virotherapy on Primary Neuroblastoma Cells
07/01/10-06/30/12$41,250

Wells, S

Fanconi Anemia and HPV Transformation
R01 CA 10235709/28/09-08/31/14$191,834
Current Year Direct$1,789,135
Industry Contracts

Fouladi, M

$30,800

Geller, J

$25,000

Weiss, B

$15,574

Absalon, M

$3,332

Cripe, T

$88,250

Wagner, L

$16,178
$1,016
Current Year Direct Receipts$180,150
Funded Collaborative Efforts

Wells, S

Fanconi Anemia as a Model for Susceptibility to Human Papillomavirus Infection
Butsch-Kovacic07/01/11-06/30/163%
Total$1,969,285